BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Findings show preserved quality of life in heavily pretreated metastatic breast cancer patients and identify potential prognostic biomarkers

Apr. 20, 2026 at 12:03pm

Got story updates? Submit your updates here. ›

An abstract, ghostly X-ray image revealing the intricate internal structures of a breast cancer cell, conveying the scientific exploration of novel prognostic markers for this challenging disease.Cutting-edge biomarker research aims to unlock new insights into the complex biology of metastatic breast cancer.San Diego Today

BriaCell Therapeutics Corp. announced it is presenting positive data from three clinical posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The presentations will include data from BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, as well as further analyses of Phase 2 data.

Why it matters

The Phase 3 clinical data shows quality of life was largely preserved in heavily pretreated metastatic breast cancer patients, an important treatment goal alongside efficacy and safety. The identification of potential prognostic biomarkers from the Phase 2 Bria-IMT study data could help stratify prognosis and guide treatment approaches for these patients.

The details

The Phase 3 data demonstrates that heavily pretreated metastatic breast cancer patients maintained overall health status and key functional measures with a favorable safety profile when treated with Bria-IMT plus an immune checkpoint inhibitor. The Phase 2 data identified a distinct subset of circulating tumor cells undergoing mitosis that correlated with more aggressive disease, as well as changes in tumor-macrophage fusion cell PD-L1 expression that may predict response to immune checkpoint inhibitor therapy.

  • The AACR Annual Meeting is taking place April 17–22, 2026 in San Diego, California.
  • BriaCell's Bria-OTS+ in Preclinical Cancer Models presentation will be on Tuesday, April 21 from 2:00- 5:00 PM PST.

The players

Saranya Chumsri, MD

Principal Investigator of BriaCell Phase 3 study of Bria-IMT+CPI, and Professor of Oncology at Mayo Clinic.

William V. Williams, MD

BriaCell's President & CEO.

BriaCell Therapeutics Corp.

A clinical-stage biotechnology company developing novel immunotherapies to transform cancer care.

Got photos? Submit your photos here. ›

What they’re saying

“Standards of care in cancer are evolving rapidly as innovative immunotherapy approaches emerge with potentially better safety profiles than chemotherapy. Clinical data, including BriaCell's, highlight that maintaining quality of life is an important treatment goal alongside efficacy and safety.”

— Saranya Chumsri, MD, Principal Investigator of BriaCell Phase 3 study of Bria-IMT+CPI, and Professor of Oncology, Mayo Clinic

“At BriaCell, we are focused on bringing novel therapeutics to cancer patients with unmet medical needs with the ultimate goal of improving patients' lives.”

— William V. Williams, MD, BriaCell's President & CEO

What’s next

Following the presentation, copies of the posters will be made available at https://briacell.com/scientific-publications/.

The takeaway

The positive Phase 3 quality of life data and identification of potential prognostic biomarkers from the Phase 2 study demonstrate BriaCell's commitment to developing innovative immunotherapies that can improve outcomes and quality of life for metastatic breast cancer patients with limited treatment options.